MedDataX Logo

Sublingual Administration of PPI

NCT ID: NCT01926600

Last Updated: 2013-08-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-08-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Compare 24-hour intragastric pH and therapeutic effectiveness of proton pump inhibitor (PPI) among different administration methods: per oral (PO), intravenous (IV), and sublingual (SL).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Low Dose Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding

NCT03814421

Peptic Ulcer Hemorrhage Peptic Ulcer, Acute With Hemorrhage Peptic Ulcer +1 more
UNKNOWN NA

Trial of Oral Versus Intravenous Proton Pump Inhibitor on Intragastric pH in Patients With Bleeding Ulcers

NCT00573924

Peptic Ulcer Hemorrhage
COMPLETED NA

Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage

NCT00037570

Peptic Ulcer Hemorrhage
COMPLETED PHASE2

Oral Versus IV Proton Pump Inhibitor in High-risk Bleeding Peptic Ulcers After Endoscopic Hemostasis

NCT01182597

Peptic Ulcers
UNKNOWN PHASE3

Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding

NCT00731601

Peptic Ulcer Hemorrhage
COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Intragastric pH and therapeutic effectiveness of PPI was compared among patients given PPI with different administration methods. 24 hour intragastric pH catheter was inserted in stomach of patients with peptic ulcer an hour prior to PPI administration in order to observe the initial change in pH. Three groups of patients were given PPI through per oral, intravenous, and sublingual administration methods. The hypothesis of this study is that sublingual administration will be faster than oral or IV administration in PPI dosing with respect to intragastric pH change and re-bleeding rate.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric or Duodenal Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PO

administrated by per oral

No interventions assigned to this group

IV

Administrated by intravenous

No interventions assigned to this group

SL

administrated by sublingual

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with peptic ulcer disease
* Age: 20-75 years old
* Patients who submitted informed consent

Exclusion Criteria

* Peptic ulcer disease with spurting and oozing
* Shock, hypotension, pregnancy
* Gastrointestinal malignancy
Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Catholic University of Korea

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jin Il Kim

MD, PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St.Mary's Hopspital of the Catholic University

Seoul, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jin Il Kim, MD

Role: CONTACT

[email protected]
82-2-3779-1519

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jin Il Kim, MD

Role: primary

[email protected]
82-2-3779-1519

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

24 hour pH

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Compare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer
NCT00471029 UNKNOWN PHASE4
Oral vs Intravenous and Proton Pump Inhibitor (PPIļ¼‰for Peptic Ulcer Bleeding (PUB)
NCT01123031 WITHDRAWN PHASE4
Effect of IV and Oral Esomeprazole in Prevention of Recurrent Bleeding From Peptic Ulcers After Endoscopic Therapy
NCT01142245 COMPLETED PHASE3
Comparison of Proton Pump Inhibitor and H2 Receptor Blocker on Prevention of Bleeding From Iatrogenic Ulcer After Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Randomized Controlled Trial
NCT01179724 UNKNOWN NA
Is Long-Term Proton Pump Inhibitor Use a Cause of Leaky Gut Syndrome
NCT06268834 COMPLETED NA
High Dose Versus Standard Dose Proton Pump Inhibitor (PPI) in High-risk Bleeding Peptic Ulcers After Combined Endoscopic Treatment
NCT00709046 UNKNOWN NA
Administration of High-Dose Intravenous Proton Pump Inhibitor for Upper Gastrointestinal Bleeding Prior to Endoscopy
NCT00164866 COMPLETED PHASE4
Comparison of Oral Rabeprazole vs. iv Omeprazole in Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding
NCT00861640 UNKNOWN PHASE4
A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer
NCT05656092 COMPLETED PHASE3
PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers
NCT05582174 RECRUITING PHASE4
Efficacy of Low Dose of Proton Pump Inhibitor in Treatment Bleeding Ulcers
NCT03163680 COMPLETED
Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer
NCT01138969 COMPLETED PHASE2
A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of PMK-S005 After Oral Administration in Healthy Male Volunteers
NCT01762397 COMPLETED PHASE1
Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage
NCT00040495 COMPLETED PHASE3
13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)
NCT00825630 COMPLETED PHASE4
Tegoprazan- Versus PPI-based H. Pylori Eradication
NCT06682533 RECRUITING
Effects of 2 Different Doses of Pantoprazole on Gastric pH and Recurrent Bleeding in Patients Who Bled From Peptic Ulcers
NCT00279123 COMPLETED PHASE4
A Comparison of Gastric pH Control With High Dose Intravenous or Oral Esomeprazole
NCT00164788 TERMINATED PHASE2
A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on MK-1084 in Healthy Adult Participants (MK-1084-003)
NCT06619314 COMPLETED PHASE1
High Dose Oral Omeprazole in High Risk UGIB
NCT04394663 RECRUITING NA
Emulation of Randomized Clinical Trial in Cardiovascular Disease
NCT06241833 RECRUITING
Gastric pH in Critically Ill Patients
NCT00590928 COMPLETED PHASE4
Gastric Functions & Proton Pump Inhibitor( PPI) Study
NCT00951431 COMPLETED PHASE4
PPI And Food Effect Study For PF-06463922 In Healthy Volunteers
NCT02569554 COMPLETED PHASE1
High Versus Standard Dose of Proton Pump Inhibitors (PPIs) in Peptic Ulcer Bleeding
NCT00374101 COMPLETED PHASE3